US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tonix Pharmaceuticals Holding Corp. - Common Stock
(NQ:
TNXP
)
8.910
-0.320 (-3.47%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tonix Pharmaceuticals Holding Corp. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA(R) Medicare Coverage to 32 Million Lives
September 22, 2026
Via
Investor Brand Network
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
↗
September 11, 2026
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved...
Via
MarketBeat
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Promotes Thomas Englese to Chief Commercial Officer
September 08, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in Cantor 2026 Global Healthcare Conference
September 02, 2026
Via
Investor Brand Network
Tonix Pharmaceuticals (NASDAQ:TNXP) Beats Revenue Estimates in First Full Quarter of TONMYA Sales
↗
May 11, 2026
Via
Chartmill
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
↗
August 18, 2026
Tonix Pharmaceuticals (NASDAQ:TNXP) is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major...
Via
MarketBeat
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript
↗
August 17, 2026
TONMYA sales hit $11 million in its second quarter on market.
Via
The Motley Fool
Topics
Earnings
Tonix Pharmaceuticals Q2 Earnings Call Highlights
↗
August 10, 2026
Tonix Pharmaceuticals (NASDAQ:TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said...
Via
MarketBeat
Topics
Earnings
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million
August 10, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million
August 10, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in August, September Investor Conferences
August 05, 2026
Via
Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Receives FDA Feedback for Lyme Disease Prevention Study
August 03, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Schedules Second-Quarter 2026 Results Call for Aug. 10
July 27, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Mpox Research Supporting TNX-801 Vaccine Development
July 15, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Medicare Coverage to 145 Million Lives
July 13, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Enrolls First Patient in Phase 2 Depression Trial
June 29, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in BTIG Infectious Disease Day 2026
June 12, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA Coverage to 52 Million Commercial Lives
June 08, 2026
Via
Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Real-World Data Highlighting Widespread Opioid Use Among Fibromyalgia Patients
May 29, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Publishes Phase 1 TNX-1500 Data Supporting Advancement into Phase 2
May 27, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Real-World Fibromyalgia Burden Data at ISPOR 2026
May 26, 2026
Via
Investor Brand Network
TechMediaBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Fibromyalgia Real-World Data at ISPOR 2026
May 14, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in Two May Investor Conferences
May 13, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q1 2026 Results, Highlights TONMYA Commercial Growth and Pipeline Progress
May 12, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Secures GPO Agreement Covering 35 Million Lives for TONMYA
May 06, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 1 Data and Plans Phase 2 Study for Lyme Disease Prevention Candidate
April 29, 2026
Via
Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Preclinical Immuno-Oncology Data At AACR 2026
April 23, 2026
Via
Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Publication of TONMYA Pharmacokinetic Study in Peer-Reviewed Journal
April 15, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 1 Data for Lyme Disease Candidate TNX-4800, Plans Phase 2 Study
March 31, 2026
Via
Investor Brand Network
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?
↗
March 30, 2026
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from late...
Via
Benzinga
Topics
Regulatory Compliance
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
